Part 4/8:
The technology's development has progressed through clinical trials, with the tenth patient receiving the Synchron Switch implant marking a crucial milestone for the company. The implant, designed to integrate seamlessly with biological surroundings, remains inside the body indefinitely. With temporary risks such as blood clots manageable through a 90-day cellular growth period, the long-term prognosis looks promising for patients eager to regain control over their technology.